文献速递白血病造血干细胞移植与细胞治疗

抗CD19 CAR-T细胞治疗急性淋巴细胞白血病的系统评价与荟萃分析

Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
PubMed 文献 · Lancet Haematol · 2020-01-01

该系统评价与荟萃分析纳入35项研究共953例复发或难治性B细胞急性淋巴细胞白血病患者,评估抗CD19 CAR-T细胞治疗的完全缓解率及安全性。3级及以上细胞因子释放综合征发生率为26%,3级及以上神经毒性为12%。

要点

  • 抗CD19 CAR-T治疗复发/难治B-ALL的汇总完全缓解率达80%。
  • 自体T细胞来源CAR-T的完全缓解率显著高于异体来源(83% vs 55%)。
  • 3级及以上细胞因子释放综合征和神经毒性发生率分别为26%和12%。

核心结论

  • 抗CD19 CAR-T细胞治疗在复发或难治性急性淋巴细胞白血病中具有高缓解率,可指导临床治疗决策。
  • 需开展对比研究以进一步明确不同抗CD19 CAR-T构建体在复发或难治性急性淋巴细胞白血病中的疗效差异。

研究设计与样本

  • 系统评价与荟萃分析,检索2012年1月1日至2020年4月14日发表的临床试验,最终纳入35项研究共953例患者。
  • 纳入标准为报告成人或儿童复发或难治性B细胞急性淋巴细胞白血病患者接受抗CD19 CAR-T细胞治疗结局的已发表或未发表临床试验,排除患者数≤2的研究。
  • 主要结局为抗CD19 CAR-T细胞输注后任意时间达到完全缓解的患者数。

主要发现

  • 不同抗CD19 CAR-T构建体间完全缓解率、细胞因子释放综合征或神经毒性发生率无差异。

临床怎么用

  • 抗CD19 CAR-T细胞治疗可用于复发或难治性急性淋巴细胞白血病,汇总完全缓解率高达80%。
  • 选择CAR-T产品时,自体T细胞来源可能具有更高的完全缓解率。
  • 需关注3级及以上细胞因子释放综合征和神经毒性,发生率分别为26%和12%。

局限性

  • 缺乏不同抗CD19 CAR-T构建体间的头对头比较研究。
  • 仅17项研究偏倚风险低,18项为中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable activity in patients with refractory or relapsed acute lymphocytic leukaemia. Various anti-CD19 CAR T-cell constructs have been trialled and responses vary widely among different studies. We aimed to systematically analyse the outcomes of patients with acute lymphocytic leukaemia treated with anti-CD19 CAR T cells and identify factors associated with differences in outcomes. METHODS: We did a systematic review and meta-analysis of published and unpublished clinical trials that reported data on the outcomes of adult or paediatric patients that were treated with anti-CD19 CAR T cells for relapsed or refractory B-cell acute lymphocytic leukaemia, reported between Jan 1, 2012, and April 14, 2020. Studies with two patients or fewer were excluded and summary data were extracted from the reports. The primary outcome was the number of patients who had complete remission at any time after anti-CD19 CAR T-cell infusion. This study is not registered in PROSPERO. FINDINGS: From 1160 studies, we identified 40 potentially appropriate studies, 35 (88%) of which met the eligibility criteria and were included in the final analysis (n=953 patients). The pooled complete remission was 80% (95% CI 75·5-84·8) and heterogeneity between studies was moderate (I2=56·96%). In the prespecified subgroup analyses, 195 (75% [95% CI 66·9-82·9, I2=35·22%]) of 263 patients in adult studies and 242 (81% [72·9-87·2, I2=54·45%]) of 346 patients in paediatric studies achieved complete remission, p=0·24. The pooled complete remission did not significantly differ with anti-CD19 CAR T-cell construct type or single-chain variable fragment clone, but was higher with autologous T-cell origin (727 [83%, 78·5-86·5, I2=44·34%] of 901 patients), compared with allogeneic T-cell origin (29 [55%, 30·6-79·0, I2=62·64%] of 52 patients; p=0·018). 242 (26% [95% CI 18·5-34·1]) of 854 patients developed grade 3 or worse cytokine release syndrome and 97 (12% [6·6-19·2]) of 532 developed grade 3 or worse neurotoxicity. There was no difference in the proportion of patients who achieved complete remission or who had cytokine release syndrome or neurotoxicity between different anti-CD19 CAR T-cell constructs. The risk of bias was assessed as low in 17 studies and moderate in 18 studies. INTERPRETATION: The high response rates after anti-CD19 CAR T-cell therapy can be used to guide the use of therapy in patients with relapsed or refractory acute lymphocytic leukaemia. Comparison studies are required to further determine differences in efficacy between different anti-CD19 CAR T-cell constructs in the setting of relapsed or refractory acute lymphocytic leukaemia. FUNDING: National Cancer Institute, National Comprehensive Cancer Network, Mayo Clinic K2R Research Pipeline, and Mayo Clinic Center for Individualized Medicine.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Anagnostou T, Riaz IB, Hashmi SK, et al. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematol. 2020. PMID: 33091355. doi:10.1016/S2352-3026(20)30277-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。